Any content you receive is for information purposes only. Always conduct your own research.*Sponsored
Heading Into Today's Session—Tuesday, March 10, 2026—
Paul Prescott has (BIAF) At The Top Of His Watchlist.
Don't Miss The Next Breakout—Get Real-Time Alerts Sent Directly
To Your Phone. Up To 10X Faster Than Email.
(BIAF) Full Coverage is Starting Today
Put (BIAF) On Your Radar While It's Still Early…
March 10, 2026
Countdown Started | See Why (BIAF) Has My Full Focus Heading into the Open
Dear Reader, Street Ideas stays focused on under-the-radar companies connected to major shifts that can start pulling in attention fast. One of the most important changes taking shape right now is in lung cancer screening, where noninvasive diagnostic technology is beginning to change how physicians approach one of the most difficult decisions in clinical care. For years, patients with suspicious lung nodules have often faced repeat scans, ongoing uncertainty, or invasive procedures that later show no cancer was present. That picture is starting to change as more advanced tools move beyond the research setting and into real-world clinical use, giving physicians a more precise way to assess risk earlier in the process. As momentum builds behind this transition, companies bringing practical diagnostic solutions to the front lines of healthcare are starting to stand out. bioAffinity Technologies, Inc. (Nasdaq: BIAF) is one of the companies operating within this shift, using flow cytometry and proprietary analysis to support the detection of early-stage malignancy. That is exactly why (BIAF) just moved onto my radar and is topping my watchlist this morning—Tuesday, March 10, 2026.
But keep in mind, (BIAF) has less than 5M shares listed as available to the public, according to MarketWatch. When companies have small public floats like this, the potential exists for big moves if demand begins to shift. This is already starting to show on the chart. (BIAF) recently made an approximate 90% move in under two weeks, from around $.73 on February 6 to $1.39 on February 19, according to data available from Barchart. 
While traditional methods often lead to invasive procedures for benign findings, the company is advancing a science-based alternative designed to improve decision-making in lung cancer diagnostics. And the deeper you look into what (BIAF) is building, the easier it becomes to see why this company is starting to draw attention. See the company's latest corporate presentation here. Here's a closer look at the technology, clinical utility, and real-world factors that are putting (BIAF) on our radar. Transforming Early Detection
bioAffinity Technologies, Inc. (Nasdaq: BIAF) is a biotechnology company focused on the noninvasive diagnosis of early-stage cancer and other diseases of the lung. The company's flagship product, CyPath® Lung, addresses a critical gap in the current healthcare system: the high rate of false positives in lung cancer screening. When a low-dose computed tomography (LDCT) scan identifies a suspicious pulmonary nodule, physicians are often forced to choose between "watchful waiting" or aggressive, invasive biopsies. CyPath® Lung changes this dynamic by analyzing a patient's sputum (phlegm) to identify cell populations indicative of cancer. The test is currently marketed as a Laboratory Developed Test (LDT) through the company's subsidiary, Precision Pathology Laboratory Services. This facility recently maintained its prestigious College of American Pathologists (CAP) accreditation, which is considered the gold standard for laboratory excellence and accuracy. By providing a 92% sensitivity and 87% specificity for detecting cancer in nodules smaller than 2 centimeters, (BIAF) is delivering a high-accuracy tool that helps physicians rule out cancer without surgery. The $10.4B Market
The U.S. lung cancer diagnostics market is projected to more than double within the next decade to reach $10.4B by 2034. This projected growth is being driven in part by a rising emphasis on early detection, as lung cancer remains the leading cause of cancer-related death worldwide. Current screening guidelines recommend annual LDCT scans for millions of high-risk individuals, yet uncertainty around scan results continues to create a significant diagnostic burden for both patients and physicians. bioAffinity Technologies, Inc. (Nasdaq: BIAF) is developing CyPath® Lung to address this challenge by providing additional clinical data after a suspicious nodule is identified. 
In recent case material, the test supported a conservative surveillance strategy for an elderly patient with a suspicious nodule. A later follow-up scan showed that the nodule had resolved, supporting the decision to avoid an invasive and costly biopsy. The ability to help rule out cancer with a high degree of confidence could become an important point of differentiation in a field where false positives often lead to unnecessary medical intervention. Platform Versatility: From Oncology to Asthma
Beyond its core lung cancer application, (BIAF) is proving that its flow cytometry platform has broad-spectrum potential. On March 3, 2026, the company presented positive research at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The data demonstrated the technology's ability to identify specific antibody receptors in sputum for leading asthma therapies, including dupilumab and benralizumab. This breakthrough suggests that the (BIAF) platform can be used to identify optimal therapies for the approximately 650M children and adults globally suffering from asthma and COPD. By matching patients with the most effective biologic therapies and monitoring inflammatory changes over time, (BIAF) is opening a new vertical in personalized medicine. This diversification reduces reliance on a single diagnostic area and positions the company as a leader in respiratory health technology. Recent Operational Achievements
Operational achievements point toward increased accessibility and commercial scale. The company recently announced a validation study with Brooke Army Medical Center (BAMC) to expand sample collection options. By validating deep suction collection alongside spontaneous cough samples, (BIAF) could significantly accelerate the adoption of CyPath® Lung in clinical settings where patients may struggle to produce a sample naturally. Results from this study are expected by mid-year 2026. Furthermore, the company's financial results for the third quarter of 2025 showcased a strategic pivot. While total revenues were $1.4M, the company reported a 122% year-over-year increase in CyPath® Lung testing revenue. This growth was driven by higher case volumes and increased adoption within the Veterans Administration (VA) health system. The company also significantly improved its balance sheet, ending the period with $7.7M in ca-sh, up from $1.1M at the end of 2024. Management and Advisory Strength
The leadership team at (BIAF) is led by Maria Zannes, a veteran executive with over 30 years of experience. She has built a team of award-winning scientists, including Chief Science Officer Dr. William Bauta, a medicinal chemist with 25 years of experience in dr-ug discovery and FDA approvals. To further guide its commercial strategy, the company recently appointed nationally recognized authorities to its Medical and Scientific Advisory Board, including specialists from MD Anderson Cancer Center and NYU Grossman School of Medicine. These experts provide independent guidance on clinical priorities and help drive the integration of CyPath® Lung into the standard of care. 7 Factors Putting (BIAF) At The Top Of This Morning's Watchlist
—Tuesday, March 10, 2026…
1. Operational Progress: Recent financial disclosures show that (BIAF) reported a 122% year-over-year increase in CyPath® Lung testing revenue while strengthening its balance sheet with $7.7M in ca-sh at the end of Q3 2025.
2. Recent Momentum: Chart data from Barchart shows that (BIAF) made an approximate 90% move in under two weeks, from about $0.73 on February 6 to $1.39 on February 19. 3. Small Float: With fewer than 5M shares listed as available to the public, (BIAF)'s small float could have the potential for big moves if demand begins to shift. 4. Growing Market: Industry projections indicate the U.S. lung cancer diagnostics market is expected to more than double to about $10.4B by 2034, placing (BIAF) within a rapidly expanding segment of healthcare diagnostics.
5. Noninvasive Detection: Through its CyPath® Lung test, (BIAF) is developing a sputum-based method designed to help identify early-stage lung malignancy without the need for invasive diagnostic procedures. 6. High Accuracy: Clinical data cited for CyPath® Lung shows that (BIAF) achieved 92% sensitivity and 87% specificity when detecting cancer in nodules smaller than 2 centimeters. 7. Platform Expansion: Research presented at the AAAAI Annual Meeting suggests the technology platform developed by (BIAF) may help identify antibody receptor responses related to leading asthma therapies. Put (BIAF) On Your Radar While It's Still Early…
(BIAF) just hit our radar for several reasons. The company has fewer than 5M shares available to the public, and small floats like this can sometimes have the potential for big moves if demand begins to shift. Recent chart activity already shows signs of momentum, with (BIAF) recently making an approximate 90% move in under two weeks. At the same time, the company is working within a lung cancer diagnostics market that industry projections suggest could more than double to about $10.4B by 2034. Beyond the market backdrop, the underlying technology is what makes this story worth understanding. CyPath® Lung is designed as a noninvasive sputum-based test that helps physicians evaluate suspicious lung nodules without immediately resorting to invasive procedures. Clinical data cited for the test reports 92% sensitivity and 87% specificity when identifying cancer in nodules smaller than 2 centimeters. On top of that, research presented earlier this month suggests the same platform may help identify antibody receptor responses connected to leading asthma therapies. Operational progress is also beginning to appear in the numbers. CyPath® Lung testing revenue increased 122% year-over-year, and the company reported $7.7M in ca-sh at the end of Q3 2025. (BIAF) is our top focus this morning—Tuesday, March 10, 2026. Take a look at (BIAF) while it's still early, and keep an eye out for my next update, it could be here very shortly. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter
| 
